Non-Hodgkin’s Lymphoma

News alerts, weekly reports and conference planners

Related cancers:

No biomarker	Small Lymphocytic Lymphoma	No biomarker	Small Lymphocytic Lymphoma	pirtobrutinib Sensitive: A1 - Approval FDA - 2 days (New A1) pirtobrutinib Sensitive : A1 FDA - 2d	pirtobrutinib Sensitive: A1 - Approval FDA - 2 days pirtobrutinib Sensitive : A1 FDA - 2 days - (New A1)
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	obinutuzumab + zanubrutinib Sensitive: A1 - Approval BeiGene Press Release - 2 weeks (New A1) obinutuzumab + zanubrutinib Sensitive : A1 BeiGene Press Release - 2wk	obinutuzumab + zanubrutinib Sensitive: A1 - Approval BeiGene Press Release - 2 weeks obinutuzumab + zanubrutinib Sensitive : A1 BeiGene Press Release - 2 weeks - (New A1)
ARID1A mutation	Non-Hodgkin’s Lymphoma	ARID1A mutation	Non-Hodgkin’s Lymphoma	CAR-T immunotherapy Resistant: C3 – Early Trials Cancer Cell Int - 2 weeks (New C3) CAR-T immunotherapy Resistant : C3 Cancer Cell Int - 2wk	CAR-T immunotherapy Resistant: C3 – Early Trials Cancer Cell Int - 2 weeks CAR-T immunotherapy Resistant : C3 Cancer Cell Int - 2 weeks - (New C3)
TP53 mutation + ARID1A mutation	Non-Hodgkin’s Lymphoma	TP53 mutation + ARID1A mutation	Non-Hodgkin’s Lymphoma	CAR-T immunotherapy Resistant: C3 – Early Trials Cancer Cell Int - 2 weeks (New C3) CAR-T immunotherapy Resistant : C3 Cancer Cell Int - 2wk	CAR-T immunotherapy Resistant: C3 – Early Trials Cancer Cell Int - 2 weeks CAR-T immunotherapy Resistant : C3 Cancer Cell Int - 2 weeks - (New C3)
No biomarker	Small Lymphocytic Lymphoma	No biomarker	Small Lymphocytic Lymphoma	lisocabtagene maraleucel Sensitive: B - Late Trials Bristol-Myers Squibb Press Release - 3 weeks (New B) lisocabtagene maraleucel Sensitive : B Bristol-Myers Squibb Press Release - 3wk	lisocabtagene maraleucel Sensitive: B - Late Trials Bristol-Myers Squibb Press Release - 3 weeks lisocabtagene maraleucel Sensitive : B Bristol-Myers Squibb Press Release - 3 weeks - (New B)
No biomarker	T Cell Non-Hodgkin Lymphoma	No biomarker	T Cell Non-Hodgkin Lymphoma	sugemalimab Sensitive: A1 - Approval CStone Pharma Press Release - 4 weeks (New A1) sugemalimab Sensitive : A1 CStone Pharma Press Release - 4wk	sugemalimab Sensitive: A1 - Approval CStone Pharma Press Release - 4 weeks sugemalimab Sensitive : A1 CStone Pharma Press Release - 4 weeks - (New A1)
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	pirtobrutinib Sensitive: A2 - Guideline NCCN - 4 weeks (New A2) pirtobrutinib Sensitive : A2 NCCN - 4wk	pirtobrutinib Sensitive: A2 - Guideline NCCN - 4 weeks pirtobrutinib Sensitive : A2 NCCN - 4 weeks - (New A2)
Chr del(17p)	Small Lymphocytic Lymphoma	Chr del(17p)	Small Lymphocytic Lymphoma	pirtobrutinib Sensitive: A2 - Guideline NCCN - 4 weeks (New A2) pirtobrutinib Sensitive : A2 NCCN - 4wk	pirtobrutinib Sensitive: A2 - Guideline NCCN - 4 weeks pirtobrutinib Sensitive : A2 NCCN - 4 weeks - (New A2)
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	SLS009 Sensitive: B - Late Trials SELLAS Life Sciences Press Release - 4 weeks (New B) SLS009 Sensitive : B SELLAS Life Sciences Press Release - 4wk	SLS009 Sensitive: B - Late Trials SELLAS Life Sciences Press Release - 4 weeks SLS009 Sensitive : B SELLAS Life Sciences Press Release - 4 weeks - (New B)
CXCR4 mutation	Waldenstrom Macroglobulinemia	CXCR4 mutation	Waldenstrom Macroglobulinemia	rituximab Sensitive: C3 – Early Trials ASH 2023 - 4 weeks (New C3) rituximab Sensitive : C3 ASH 2023 - 4wk	rituximab Sensitive: C3 – Early Trials ASH 2023 - 4 weeks rituximab Sensitive : C3 ASH 2023 - 4 weeks - (New C3)
CD5 positive	Diffuse Large B Cell Lymphoma	CD5 positive	Diffuse Large B Cell Lymphoma	methotrexate Sensitive: C3 – Early Trials ASH 2023 - 4 weeks (New C3) methotrexate Sensitive : C3 ASH 2023 - 4wk	methotrexate Sensitive: C3 – Early Trials ASH 2023 - 4 weeks methotrexate Sensitive : C3 ASH 2023 - 4 weeks - (New C3)
CCND1 expression	Diffuse Large B Cell Lymphoma	CCND1 expression	Diffuse Large B Cell Lymphoma	R-CHOP Resistant: C3 – Early Trials ASH 2023 - 4 weeks (New C3) R-CHOP Resistant : C3 ASH 2023 - 4wk	R-CHOP Resistant: C3 – Early Trials ASH 2023 - 4 weeks R-CHOP Resistant : C3 ASH 2023 - 4 weeks - (New C3)
MYD88 L265P	Diffuse Large B Cell Lymphoma	MYD88 L265P	Diffuse Large B Cell Lymphoma	ZPR Sensitive: C3 – Early Trials ASH 2023 - 4 weeks (New C3) ZPR Sensitive : C3 ASH 2023 - 4wk	ZPR Sensitive: C3 – Early Trials ASH 2023 - 4 weeks ZPR Sensitive : C3 ASH 2023 - 4 weeks - (New C3)
TNFRSF8 positive	Cutaneous T-cell Lymphoma	TNFRSF8 positive	Cutaneous T-cell Lymphoma	gemcitabine + doxorubicin hydrochloride Sensitive: C3 – Early Trials ASH 2023 - 4 weeks (New C3) gemcitabine + doxorubicin hydrochloride Sensitive : C3 ASH 2023 - 4wk	gemcitabine + doxorubicin hydrochloride Sensitive: C3 – Early Trials ASH 2023 - 4 weeks gemcitabine + doxorubicin hydrochloride Sensitive : C3 ASH 2023 - 4 weeks - (New C3)
ALK positive	Diffuse Large B Cell Lymphoma	ALK positive	Diffuse Large B Cell Lymphoma	lorlatinib Sensitive: C3 – Early Trials ASH 2023 - 4 weeks (New C3) lorlatinib Sensitive : C3 ASH 2023 - 4wk	lorlatinib Sensitive: C3 – Early Trials ASH 2023 - 4 weeks lorlatinib Sensitive : C3 ASH 2023 - 4 weeks - (New C3)
PD-L1 expression	Diffuse Large B Cell Lymphoma	PD-L1 expression	Diffuse Large B Cell Lymphoma	R-CHOP Sensitive: C3 – Early Trials ASH 2023 - 4 weeks (New C3) R-CHOP Sensitive : C3 ASH 2023 - 4wk	R-CHOP Sensitive: C3 – Early Trials ASH 2023 - 4 weeks R-CHOP Sensitive : C3 ASH 2023 - 4 weeks - (New C3)
TP53 mutation	Marginal Zone Lymphoma	TP53 mutation	Marginal Zone Lymphoma	ibrutinib Resistant: C3 – Early Trials ASH 2023 - 4 weeks (New C3) ibrutinib Resistant : C3 ASH 2023 - 4wk	ibrutinib Resistant: C3 – Early Trials ASH 2023 - 4 weeks ibrutinib Resistant : C3 ASH 2023 - 4 weeks - (New C3)
LDH elevation	Marginal Zone Lymphoma	LDH elevation	Marginal Zone Lymphoma	ibrutinib Resistant: C3 – Early Trials ASH 2023 - 4 weeks (New C3) ibrutinib Resistant : C3 ASH 2023 - 4wk	ibrutinib Resistant: C3 – Early Trials ASH 2023 - 4 weeks ibrutinib Resistant : C3 ASH 2023 - 4 weeks - (New C3)
TP53 deletion	Marginal Zone Lymphoma	TP53 deletion	Marginal Zone Lymphoma	ibrutinib Resistant: C3 – Early Trials ASH 2023 - 4 weeks (New C3) ibrutinib Resistant : C3 ASH 2023 - 4wk	ibrutinib Resistant: C3 – Early Trials ASH 2023 - 4 weeks ibrutinib Resistant : C3 ASH 2023 - 4 weeks - (New C3)
BCL2 positive	Diffuse Large B Cell Lymphoma	BCL2 positive	Diffuse Large B Cell Lymphoma	venetoclax + polatuzumab vedotin-piiq Sensitive: C3 – Early Trials ASH 2023 - 4 weeks (New C3) venetoclax + polatuzumab vedotin-piiq Sensitive : C3 ASH 2023 - 4wk	venetoclax + polatuzumab vedotin-piiq Sensitive: C3 – Early Trials ASH 2023 - 4 weeks venetoclax + polatuzumab vedotin-piiq Sensitive : C3 ASH 2023 - 4 weeks - (New C3)
CDCA2 overexpression	Diffuse Large B Cell Lymphoma	CDCA2 overexpression	Diffuse Large B Cell Lymphoma	R-CHOP + bortezomib Sensitive: C3 – Early Trials ASH 2023 - 4 weeks (New C3) R-CHOP + bortezomib Sensitive : C3 ASH 2023 - 4wk	R-CHOP + bortezomib Sensitive: C3 – Early Trials ASH 2023 - 4 weeks R-CHOP + bortezomib Sensitive : C3 ASH 2023 - 4 weeks - (New C3)
TP53 mutation	Mantle Cell Lymphoma	TP53 mutation	Mantle Cell Lymphoma	BOVen Sensitive: C3 – Early Trials ASH 2023 - 4 weeks (New C3) BOVen Sensitive : C3 ASH 2023 - 4wk	BOVen Sensitive: C3 – Early Trials ASH 2023 - 4 weeks BOVen Sensitive : C3 ASH 2023 - 4 weeks - (New C3)
TMB-H	Diffuse Large B Cell Lymphoma	TMB-H	Diffuse Large B Cell Lymphoma	Immunotherapy Sensitive: C3 – Early Trials ASH 2023 - 4 weeks (New C3) Immunotherapy Sensitive : C3 ASH 2023 - 4wk	Immunotherapy Sensitive: C3 – Early Trials ASH 2023 - 4 weeks Immunotherapy Sensitive : C3 ASH 2023 - 4 weeks - (New C3)
TP53 mutation	Mantle Cell Lymphoma	TP53 mutation	Mantle Cell Lymphoma	lisocabtagene maraleucel Sensitive: C3 – Early Trials - 4 weeks (New C3) lisocabtagene maraleucel Sensitive : C3 - 4wk	lisocabtagene maraleucel Sensitive: C3 – Early Trials - 4 weeks lisocabtagene maraleucel Sensitive : C3 - 4 weeks - (New C3)
CD19 positive	Follicular Lymphoma	CD19 positive	Follicular Lymphoma	acalabrutinib + axicabtagene ciloleucel Sensitive: C3 – Early Trials ASH 2023 - 4 weeks (New C3) acalabrutinib + axicabtagene ciloleucel Sensitive : C3 ASH 2023 - 4wk	acalabrutinib + axicabtagene ciloleucel Sensitive: C3 – Early Trials ASH 2023 - 4 weeks acalabrutinib + axicabtagene ciloleucel Sensitive : C3 ASH 2023 - 4 weeks - (New C3)
CD19 positive	Diffuse Large B Cell Lymphoma	CD19 positive	Diffuse Large B Cell Lymphoma	acalabrutinib + axicabtagene ciloleucel Sensitive: C3 – Early Trials ASH 2023 - 4 weeks (New C3) acalabrutinib + axicabtagene ciloleucel Sensitive : C3 ASH 2023 - 4wk	acalabrutinib + axicabtagene ciloleucel Sensitive: C3 – Early Trials ASH 2023 - 4 weeks acalabrutinib + axicabtagene ciloleucel Sensitive : C3 ASH 2023 - 4 weeks - (New C3)
MYD88 mutation	Waldenstrom Macroglobulinemia	MYD88 mutation	Waldenstrom Macroglobulinemia	BTK inhibitor Sensitive: C3 – Early Trials ASH 2023 - 4 weeks (New C3) BTK inhibitor Sensitive : C3 ASH 2023 - 4wk	BTK inhibitor Sensitive: C3 – Early Trials ASH 2023 - 4 weeks BTK inhibitor Sensitive : C3 ASH 2023 - 4 weeks - (New C3)
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	M7583 Sensitive: C3 – Early Trials ASH 2023 - 4 weeks (New C3) M7583 Sensitive : C3 ASH 2023 - 4wk	M7583 Sensitive: C3 – Early Trials ASH 2023 - 4 weeks M7583 Sensitive : C3 ASH 2023 - 4 weeks - (New C3)
Chr del(17p)	Small Lymphocytic Lymphoma	Chr del(17p)	Small Lymphocytic Lymphoma	M7583 Sensitive: C3 – Early Trials ASH 2023 - 4 weeks (New C3) M7583 Sensitive : C3 ASH 2023 - 4wk	M7583 Sensitive: C3 – Early Trials ASH 2023 - 4 weeks M7583 Sensitive : C3 ASH 2023 - 4 weeks - (New C3)
CD19 expression	Mantle Cell Lymphoma	CD19 expression	Mantle Cell Lymphoma	IKS03 Sensitive: D – Preclinical ASH 2023 - 4 weeks (New D) IKS03 Sensitive : D ASH 2023 - 4wk	IKS03 Sensitive: D – Preclinical ASH 2023 - 4 weeks IKS03 Sensitive : D ASH 2023 - 4 weeks - (New D)
CD19 expression	Diffuse Large B Cell Lymphoma	CD19 expression	Diffuse Large B Cell Lymphoma	IKS03 Sensitive: D – Preclinical ASH 2023 - 4 weeks (New D) IKS03 Sensitive : D ASH 2023 - 4wk	IKS03 Sensitive: D – Preclinical ASH 2023 - 4 weeks IKS03 Sensitive : D ASH 2023 - 4 weeks - (New D)
CD38 expression	Peripheral T-cell Lymphoma	CD38 expression	Peripheral T-cell Lymphoma	SAR442257 Sensitive: D – Preclinical ASH 2023 - 4 weeks (New D) SAR442257 Sensitive : D ASH 2023 - 4wk	SAR442257 Sensitive: D – Preclinical ASH 2023 - 4 weeks SAR442257 Sensitive : D ASH 2023 - 4 weeks - (New D)
CD28 expression	Peripheral T-cell Lymphoma	CD28 expression	Peripheral T-cell Lymphoma	SAR442257 Sensitive: D – Preclinical ASH 2023 - 4 weeks (New D) SAR442257 Sensitive : D ASH 2023 - 4wk	SAR442257 Sensitive: D – Preclinical ASH 2023 - 4 weeks SAR442257 Sensitive : D ASH 2023 - 4 weeks - (New D)
BTK C481S	Diffuse Large B Cell Lymphoma	BTK C481S	Diffuse Large B Cell Lymphoma	ABBV-101 Sensitive: D – Preclinical ASH 2023 - 4 weeks (New D) ABBV-101 Sensitive : D ASH 2023 - 4wk	ABBV-101 Sensitive: D – Preclinical ASH 2023 - 4 weeks ABBV-101 Sensitive : D ASH 2023 - 4 weeks - (New D)
MYD88 mutation	Diffuse Large B Cell Lymphoma	MYD88 mutation	Diffuse Large B Cell Lymphoma	pacritinib Sensitive: D – Preclinical ASH 2023 - 4 weeks (New D) pacritinib Sensitive : D ASH 2023 - 4wk	pacritinib Sensitive: D – Preclinical ASH 2023 - 4 weeks pacritinib Sensitive : D ASH 2023 - 4 weeks - (New D)
ROR1 overexpression	Mantle Cell Lymphoma	ROR1 overexpression	Mantle Cell Lymphoma	ONCT-808 Sensitive: D – Preclinical SITC 2023 - 4 weeks (New D) ONCT-808 Sensitive : D SITC 2023 - 4wk	ONCT-808 Sensitive: D – Preclinical SITC 2023 - 4 weeks ONCT-808 Sensitive : D SITC 2023 - 4 weeks - (New D)
CD19 underexpression	Non-Hodgkin’s Lymphoma	CD19 underexpression	Non-Hodgkin’s Lymphoma	CLN-978 Sensitive: D – Preclinical SITC 2023 - 4 weeks (New D) CLN-978 Sensitive : D SITC 2023 - 4wk	CLN-978 Sensitive: D – Preclinical SITC 2023 - 4 weeks CLN-978 Sensitive : D SITC 2023 - 4 weeks - (New D)
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Mediastinal B Cell Lymphoma	No biomarker	Mediastinal B Cell Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	brexucabtagene autoleucel Sensitive: A1 - Approval brexucabtagene autoleucel Sensitive : A1	brexucabtagene autoleucel Sensitive: A1 - Approval brexucabtagene autoleucel Sensitive : A1
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1
No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
ALK positive	Non-Hodgkin’s Lymphoma	ALK positive	Non-Hodgkin’s Lymphoma	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	tisagenlecleucel-T Sensitive: A1 - Approval tisagenlecleucel-T Sensitive : A1	tisagenlecleucel-T Sensitive: A1 - Approval tisagenlecleucel-T Sensitive : A1
CD20 positive	Diffuse Large B Cell Lymphoma	CD20 positive	Diffuse Large B Cell Lymphoma	Rixathon (rituximab biosimilar) Sensitive: A1 - Approval Rixathon (rituximab biosimilar) Sensitive : A1	Rixathon (rituximab biosimilar) Sensitive: A1 - Approval Rixathon (rituximab biosimilar) Sensitive : A1
No biomarker	Burkitt Lymphoma	No biomarker	Burkitt Lymphoma	cyclophosphamide Sensitive: A1 - Approval cyclophosphamide Sensitive : A1	cyclophosphamide Sensitive: A1 - Approval cyclophosphamide Sensitive : A1
No biomarker	Burkitt Lymphoma	No biomarker	Burkitt Lymphoma	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	orelabrutinib Sensitive: A1 - Approval orelabrutinib Sensitive : A1	orelabrutinib Sensitive: A1 - Approval orelabrutinib Sensitive : A1
No biomarker	Small Lymphocytic Lymphoma	No biomarker	Small Lymphocytic Lymphoma	orelabrutinib Sensitive: A1 - Approval orelabrutinib Sensitive : A1	orelabrutinib Sensitive: A1 - Approval orelabrutinib Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	lenalidomide Sensitive: A1 - Approval lenalidomide Sensitive : A1	lenalidomide Sensitive: A1 - Approval lenalidomide Sensitive : A1
CD20 expression	Non-Hodgkin’s Lymphoma	CD20 expression	Non-Hodgkin’s Lymphoma	rituximab-arrx Sensitive: A1 - Approval rituximab-arrx Sensitive : A1	rituximab-arrx Sensitive: A1 - Approval rituximab-arrx Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1
No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
CD20 positive	Diffuse Large B Cell Lymphoma	CD20 positive	Diffuse Large B Cell Lymphoma	rituximab-abbs Sensitive: A1 - Approval rituximab-abbs Sensitive : A1	rituximab-abbs Sensitive: A1 - Approval rituximab-abbs Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	rituximab-abbs Sensitive: A1 - Approval rituximab-abbs Sensitive : A1	rituximab-abbs Sensitive: A1 - Approval rituximab-abbs Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	Rixathon (rituximab biosimilar) Sensitive: A1 - Approval Rixathon (rituximab biosimilar) Sensitive : A1	Rixathon (rituximab biosimilar) Sensitive: A1 - Approval Rixathon (rituximab biosimilar) Sensitive : A1
CD20 positive	Diffuse Large B Cell Lymphoma	CD20 positive	Diffuse Large B Cell Lymphoma	rituximab-pvvr Sensitive: A1 - Approval rituximab-pvvr Sensitive : A1	rituximab-pvvr Sensitive: A1 - Approval rituximab-pvvr Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	rituximab-pvvr Sensitive: A1 - Approval rituximab-pvvr Sensitive : A1	rituximab-pvvr Sensitive: A1 - Approval rituximab-pvvr Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	obinutuzumab Sensitive: A1 - Approval obinutuzumab Sensitive : A1	obinutuzumab Sensitive: A1 - Approval obinutuzumab Sensitive : A1
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1
No biomarker	Small Lymphocytic Lymphoma	No biomarker	Small Lymphocytic Lymphoma	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	temsirolimus Sensitive: A1 - Approval temsirolimus Sensitive : A1	temsirolimus Sensitive: A1 - Approval temsirolimus Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	rituximab + polatuzumab vedotin-piiq Sensitive: A1 - Approval rituximab + polatuzumab vedotin-piiq Sensitive : A1	rituximab + polatuzumab vedotin-piiq Sensitive: A1 - Approval rituximab + polatuzumab vedotin-piiq Sensitive : A1
No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	pixantrone Sensitive: A1 - Approval pixantrone Sensitive : A1	pixantrone Sensitive: A1 - Approval pixantrone Sensitive : A1

Non-Hodgkin’s Lymphoma

Associations(1003)

Associations
(1003)